Table 1.
Demographic and clinical characteristics of patients at baseline (N = 25)
| Characteristic | n | % |
|---|---|---|
| Age, years | ||
| Median | 57 | |
| Range | 41–75 | |
| Status of menopause | ||
| Premenopause | 5 | 20.0 |
| Postmenopause | 20 | 80.0 |
| Stage | ||
| IV | 8 | 32.0 |
| Recurrence after surgery | 17 | 68.0 |
| ECOG performance status | ||
| 0 | 24 | 96.0 |
| 1 | 1 | 4.0 |
| Histopathology | ||
| Common type | 25 | 100.0 |
| ER status | ||
| Positive | 12 | 48.0 |
| Negative | 13 | 52.0 |
| PgR status | ||
| Positive | 5 | 20.0 |
| Negative | 20 | 80.0 |
| HER2 status | ||
| Herceptest®/FISH or DISH | ||
| 3+/not evaluable | 11 | 44.0 |
| 3+/positive | 8 | 32.0 |
| 2+/positive | 5 | 20.0 |
| Not evaluable/positive | 1 | 4.0 |
| Prior adjuvant or neoadjuvant chemotherapy with anthracyclines | ||
| Present | 13 | 52.0 |
| Absent | 12 | 48.0 |
| Prior adjuvant or neoadjuvant chemotherapy with taxanes | ||
| Present | 15 | 60.0 |
| Absent | 10 | 40.0 |
| Prior adjuvant or neoadjuvant chemotherapy with trastuzumab | ||
| Absent | 11 | 44.0 |
| Prior adjuvant or neoadjuvant hormone therapy | ||
| Present | 9 | 36.0 |
| Absent | 16 | 64.0 |
| Current hormone therapy | ||
| Present | 2 | 8.0 |
| Absent | 23 | 92.0 |
| Combination treatment with bone mineral modifiers | ||
| Denosumab | 3 | 12.0 |
| Zolodronate | 2 | 8.0 |
| Metastatic sites | ||
| 3 | 8 | 32.0 |
| 4 | 2 | 8.0 |
| Visceral metastases | ||
| Present | 14 | 56.0 |
| Absent | 11 | 44.0 |
| Lung metastasis | ||
| Present | 9 | 36.0 |
| Absent | 16 | 64.0 |
| Liver metastasis | ||
| Present | 9 | 36.0 |
| Absent | 16 | 64.0 |
| Local lesion | ||
| Present | 12 | 48.0 |
| Absent | 13 | 52.0 |
| Lymph node metastasis | ||
| Present | 16 | 64.0 |
| Absent | 9 | 36.0 |
| Skin metastasis | ||
| Present | 3 | 12.0 |
| Absent | 22 | 88.0 |
| Bone metastasis | ||
| Present | 6 | 24.0 |
| Absent | 19 | 76.0 |
ECOG Eastern Cooperative Oncology Group, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2, FISH fluorescence in situ hybridization, DISH dual-color in situ hybridization